AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced the launch of Fetal Focus, a noninvasive prenatal test ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, and MyOme, a leading clinical whole genome analysis and polygenic risk modeling ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced an ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on its 385-gene kidney ...

Natera's robust financial performance, driven by strong growth in its Women’s Health and Oncology segments, justifies its recent stock price surge and positive outlook. The company’s strategic ...

AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly ...

During Chapman’s 15-year tenure at Natera, the company has published more than 250 peer-reviewed papers and launched 20 products that have transformed patient care, including two of the fastest ...

When Mara Varona was pregnant she decided to take a common prenatal blood test to screen for genetic conditions. It was part of a proactive approach she and her husband took to pregnancy. "We're just ...

Genetic testing company Natera (NASDAQ:NTRA). announced in Q1 CY2025, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98 billion at the midpoint came ...

When Mara Varona was pregnant she decided to take a common prenatal blood test to screen for genetic conditions. It was part of a proactive approach she and her husband took to pregnancy. "We're just ...